BioCryst Pharma (BCRX) Balance Sheet

Click line-items for a historical chart and %

Assets
Cash and cash equivalents	35.39M
Restricted cash	1.51M
Marketable securities	17.43M
Receivables from collaborations
Interest reserve
Inventories	2.23M
Prepaid expenses and other current assets	2.01M
Deferred collaboration expense	98K
Total current assets	64.63M
Marketable securities	14.37M
Furniture and equipment, net	10.1M
Deferred collaboration expense	214K
Other assets	2.19M
Total assets	91.5M
Liabilities and Stockholders' Equity
Accounts payable	2.76M
Accrued expenses	10.78M
Interest payable	7.56M
Deferred collaboration revenue	2.28M
Total current liabilities	51.52M
Deferred rent	265K
Deferred collaboration revenue	8.48M
Foreign currency derivative
Non-recourse notes payable
Commitments and contingencies
Stockholders' equity:
Preferred stock: 5,000 shares authorized; none issued and outstanding	0
Common stock, $.01 par value: shares authorized - 95,000; shares issued and outstanding - 45,150 in 2011 and 44,959 in 2010	738K
Additional paid-in capital
Accumulated other comprehensive income	22K
Accumulated deficit	-561.56M
Total stockholders' equity	3.99M
Total liabilities and stockholders' equity	91.5M

Entities mentioned with BCRX